Impaired CD95 Expression Predisposes for Recurrence in Curatively Resected Colon Carcinoma: Clinical Evidence for Immunoselection and CD95L Mediated Control of Minimal Residual Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Apr 16

PMID 15831912

Citations 36

Authors

J Strater

U Hinz

C Hasel

U Bhanot

G Mechtersheimer

T Lehnert

P Moller

Affiliations

Soon will be listed here.

Abstract

Background: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression. On the other hand, neo-expression of CD95L in tumour cells may contribute to immune evasion.

Aims: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.

Patients And Methods: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.

Results: CD95 expression in tumour cells was observed in only 30 carcinomas (23.4%) whereas the others had at least a minor subpopulation of CD95 negative cells. Loss of CD95 in tumour cells was related to adverse prognosis in uni- and multivariate analysis (p = 0.046 and p = 0.036, respectively). Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas. CD95L+TIL were present in 83% of cases whereas CD95L was found in tumour cells in only 12% of cases. Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.

Conclusions: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas. The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.

Citing Articles

Role of metalloproteases in the CD95 signaling pathways.

Devel L, Guedeney N, Bregant S, Chowdhury A, Jean M, Legembre P Front Immunol. 2022; 13:1074099.

PMID: 36544756 PMC: 9760969. DOI: 10.3389/fimmu.2022.1074099.

Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth .

Al Subeh Z, Poschel D, Redd P, Klement J, Merting A, Yang D ACS Nano. 2022; 16(8):12695-12710.

PMID: 35939651 PMC: 9721370. DOI: 10.1021/acsnano.2c04420.

MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance.

Massaro C, Safadeh E, Sgueglia G, Stunnenberg H, Altucci L, DellAversana C Cells. 2021; 10(1).

PMID: 33396628 PMC: 7823834. DOI: 10.3390/cells10010039.

Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Saha N, Muntean A Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188498.

PMID: 33373647 PMC: 7856268. DOI: 10.1016/j.bbcan.2020.188498.

SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Lu C, Klement J, Yang D, Albers T, Lebedyeva I, Waller J Cancer Lett. 2020; 476:87-96.

PMID: 32061753 PMC: 7138631. DOI: 10.1016/j.canlet.2020.02.004.

References

Younes M, Schwartz M, Finnie D, Younes A . Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol. 1999; 30(11):1309-13. DOI: 10.1016/s0046-8177(99)90061-8. View

Strater J, Walczak H, Hasel C, Melzner I, Leithauser F, Moller P . CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ. 2001; 8(3):273-8. DOI: 10.1038/sj.cdd.4400813. View

Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B . Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol. 2000; 164(10):5023-7. DOI: 10.4049/jimmunol.164.10.5023. View

Ryu B, Lee M, Chi S, Kim Y, Park J . Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol. 2001; 194(1):15-9. DOI: 10.1002/path.835. View

Screpanti V, Wallin R, Ljunggren H, Grandien A . A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001; 167(4):2068-73. DOI: 10.4049/jimmunol.167.4.2068. View

Maecker H, Yun Z, Maecker H, Giaccia A . Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell. 2002; 2(2):139-48. DOI: 10.1016/s1535-6108(02)00095-8. View

Liu K, Abrams S . Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol. 2003; 170(12):5973-80. DOI: 10.4049/jimmunol.170.12.5973. View

Kim H, Lee J, Soung Y, Park W, Kim S, Lee J . Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology. 2003; 125(3):708-15. DOI: 10.1016/s0016-5085(03)01059-x. View

Liu K, McDuffie E, Abrams S . Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol. 2003; 171(8):4164-74. DOI: 10.4049/jimmunol.171.8.4164. View

10.

Nacopoulou L, Azaris P, PAPACHARALAMPOUS N, Davaris P . Prognostic significance of histologic host response in cancer of the large bowel. Cancer. 1981; 47(5):930-6. DOI: 10.1002/1097-0142(19810301)47:5<930::aid-cncr2820470519>3.0.co;2-1. View

11.

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M . The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991; 66(2):233-43. DOI: 10.1016/0092-8674(91)90614-5. View

12.

Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C . Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992; 267(15):10709-15. View

13.

Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C . Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993; 69(4):415-29. View

14.

Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A . Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994; 57(3):371-7. DOI: 10.1002/ijc.2910570314. View

15.

Takeuchi T, Sasaki Y, Ueki T, Kaziwara T, Moriyama N, Kawabe K . Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Int J Cancer. 1996; 67(5):709-14. DOI: 10.1002/(SICI)1097-0215(19960904)67:5<709::AID-IJC20>3.0.CO;2-Z. View

16.

Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French L . Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996; 274(5291):1363-6. DOI: 10.1126/science.274.5291.1363. View

17.

OConnell J, OSullivan G, Collins J, Shanahan F . The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996; 184(3):1075-82. PMC: 2192789. DOI: 10.1084/jem.184.3.1075. View

18.

Peng S, Robert M, Hayday A, Craft J . A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med. 1996; 184(3):1149-54. PMC: 2192794. DOI: 10.1084/jem.184.3.1149. View

19.

Nagata S . Apoptosis by death factor. Cell. 1997; 88(3):355-65. DOI: 10.1016/s0092-8674(00)81874-7. View

20.

Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A . CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology. 1997; 113(1):160-7. DOI: 10.1016/s0016-5085(97)70091-x. View